Literature DB >> 26375617

Systematic review of sarcopenia in patients operated on for gastrointestinal and hepatopancreatobiliary malignancies.

S Levolger1, J L A van Vugt1, R W F de Bruin1, J N M IJzermans1.   

Abstract

BACKGROUND: Preoperative risk assessment in cancer surgery is of importance to improve treatment and outcome. The aim of this study was to assess the impact of CT-assessed sarcopenia on short- and long-term outcomes in patients undergoing surgical resection of gastrointestinal and hepatopancreatobiliary malignancies.
METHODS: A systematic search of Embase, PubMed and Web of Science was performed to identify relevant studies published before 30 September 2014. PRISMA guidelines for systematic reviews were followed. Screening for inclusion, checking the validity of included studies and data extraction were carried out independently by two investigators.
RESULTS: After screening 692 records, 13 observational studies with a total of 2884 patients were included in the analysis. There was wide variation in the reported prevalence of sarcopenia (17.0-79 per cent). Sarcopenia was independently associated with reduced overall survival in seven of ten studies, irrespective of tumour site. Hazard ratios (HRs) of up to 3.19 (hepatic cancer), 1.63 (pancreatic cancer), 1.85 (colorectal cancer) and 2.69 (colorectal liver metastases, CLM) were reported. For oesophageal cancer, the HR was 0.31 for increasing muscle mass. In patients with colorectal cancer and CLM, sarcopenia was independently associated with postoperative mortality (colorectal cancer: odds ratio (OR) 43.3), complications (colorectal cancer: OR 0.96 for increasing muscle mass; CLM: OR 2.22) and severe complications (CLM: OR 3.12).
CONCLUSION: Sarcopenia identified before surgery by single-slice CT is associated with impaired overall survival in gastrointestinal and hepatopancreatobiliary malignancies, and increased postoperative morbidity in patients with colorectal cancer with or without hepatic metastases.
© 2015 BJS Society Ltd Published by John Wiley & Sons Ltd.

Entities:  

Mesh:

Year:  2015        PMID: 26375617     DOI: 10.1002/bjs.9893

Source DB:  PubMed          Journal:  Br J Surg        ISSN: 0007-1323            Impact factor:   6.939


  72 in total

Review 1.  Sarcopenia predicts worse postoperative outcomes and decreased survival rates in patients with colorectal cancer: a systematic review and meta-analysis.

Authors:  Mario Trejo-Avila; Katya Bozada-Gutiérrez; Carlos Valenzuela-Salazar; Jesús Herrera-Esquivel; Mucio Moreno-Portillo
Journal:  Int J Colorectal Dis       Date:  2021-01-22       Impact factor: 2.571

2.  Skeletal muscle loss during anti-EGFR combined chemotherapy regimens predicts poor prognosis in patients with RAS wild metastatic colorectal cancer.

Authors:  O Köstek; N C Demircan; A Gökyer; A Küçükarda; B S Sunal; M B Hacıoğlu; H Eslame; S Solak; E Yılmaz; S Uzunoğlu; N Tunçbilek; I Çiçin; B Erdoğan
Journal:  Clin Transl Oncol       Date:  2019-03-28       Impact factor: 3.405

3.  Sarcopenia defined by muscle quality rather than quantity predicts complications following laparoscopic right hemicolectomy.

Authors:  James Tankel; Shlomo Yellinek; Elena Vainberg; Yotam David; Dmitry Greenman; James Kinross; Petachia Reissman
Journal:  Int J Colorectal Dis       Date:  2019-11-27       Impact factor: 2.571

4.  Sarcopenia predicts poor postoperative outcome in elderly patients with lung cancer.

Authors:  Yo Kawaguchi; Jun Hanaoka; Yasuhiko Ohshio; Keigo Okamoto; Ryosuke Kaku; Kazuki Hayashi; Takuya Shiratori; Makoto Yoden
Journal:  Gen Thorac Cardiovasc Surg       Date:  2019-04-10

5.  Effect of pretreatment psoas muscle mass on survival for patients with unresectable pancreatic cancer undergoing systemic chemotherapy.

Authors:  Noriko Ishii; Yoshinori Iwata; Hiroki Nishikawa; Hirayuki Enomoto; Nobuhiro Aizawa; Akio Ishii; Yuho Miyamoto; Yukihisa Yuri; Kunihiro Hasegawa; Chikage Nakano; Takashi Nishimura; Kazunori Yoh; Yoshiyuki Sakai; Naoto Ikeda; Tomoyuki Takashima; Ryo Takata; Hiroko Iijima; Shuhei Nishiguchi
Journal:  Oncol Lett       Date:  2017-09-15       Impact factor: 2.967

6.  Anthropometric Changes in Patients with Pancreatic Cancer Undergoing Preoperative Therapy and Pancreatoduodenectomy.

Authors:  Jordan M Cloyd; Graciela M Nogueras-González; Laura R Prakash; Maria Q B Petzel; Nathan H Parker; An T Ngo-Huang; David Fogelman; Jason W Denbo; Naveen Garg; Michael P Kim; Jeffrey E Lee; Ching-Wei D Tzeng; Jason B Fleming; Matthew H G Katz
Journal:  J Gastrointest Surg       Date:  2017-12-11       Impact factor: 3.452

7.  Prognostic significance of sarcopenia in patients with hepatocellular carcinoma undergoing sorafenib therapy.

Authors:  Hiroki Nishikawa; Norihiro Nishijima; Hirayuki Enomoto; Azusa Sakamoto; Akihiro Nasu; Hideyuki Komekado; Takashi Nishimura; Ryuichi Kita; Toru Kimura; Hiroko Iijima; Shuhei Nishiguchi; Yukio Osaki
Journal:  Oncol Lett       Date:  2017-05-31       Impact factor: 2.967

8.  Sarcopenia is an independent predictor of complications after colorectal cancer surgery.

Authors:  Ryota Nakanishi; Eiji Oki; Shun Sasaki; Kosuke Hirose; Tomoko Jogo; Keitaro Edahiro; Shotaro Korehisa; Daisuke Taniguchi; Kensuke Kudo; Junji Kurashige; Masahiko Sugiyama; Yuichiro Nakashima; Kippei Ohgaki; Hiroshi Saeki; Yoshihiko Maehara
Journal:  Surg Today       Date:  2017-07-11       Impact factor: 2.549

9.  Decreased Skeletal Muscle Volume Is a Predictive Factor for Poorer Survival in Patients Undergoing Surgical Resection for Pancreatic Ductal Adenocarcinoma.

Authors:  Motokazu Sugimoto; Michael B Farnell; David M Nagorney; Michael L Kendrick; Mark J Truty; Rory L Smoot; Suresh T Chari; Michael R Moynagh; Gloria M Petersen; Rickey E Carter; Naoki Takahashi
Journal:  J Gastrointest Surg       Date:  2018-02-01       Impact factor: 3.452

10.  Sarcopenia predicts 1-year mortality in elderly patients undergoing curative gastrectomy for gastric cancer: a prospective study.

Authors:  Dong-Dong Huang; Xiao-Xi Chen; Xi-Yi Chen; Su-Lin Wang; Xian Shen; Xiao-Lei Chen; Zhen Yu; Cheng-Le Zhuang
Journal:  J Cancer Res Clin Oncol       Date:  2016-08-29       Impact factor: 4.553

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.